Prevention and Therapy of Metastatic HER-2⁺ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine

Vaccines are a promising therapeutic alternative to monoclonal antibodies against HER-2⁺ breast cancer. We present the preclinical activity of an ES2B-C001, a VLP-based vaccine being developed for human breast cancer therapy. FVB mice challenged with HER-2⁺ mammary carcinoma ce...

Descripció completa

Dades bibliogràfiques

Autors principals:	Francesca Ruzzi, Arianna Palladini, Stine Clemmensen, Anette Strøbæk, Nicolaas Buijs, Tanja Domeyer, Jerzy Dorosz, Vladislav Soroka, Dagmara Grzadziela, Christina Jo Rasmussen, Ida Busch Nielsen, Max Soegaard, Maria Sofia Semprini, Laura Scalambra, Stefania Angelicola, Lorena Landuzzi, Pier-Luigi Lollini, Mette Thorn
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2022-10-01
Col·lecció:	Biomedicines
Matèries:	breast cancer vaccine virus-like particles (cVLP) HER-2 tyrosine kinase receptor target therapies
Accés en línia:	https://www.mdpi.com/2227-9059/10/10/2654
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!